Blis Technologies Limited · NZX:BLT
Blis Technologies — Shareholder Meeting (July 2020)
37 slides from Blis Technologies's shareholder meeting presentation, Jul 24, 2020
Slide 1: Annual Shareholder Meeting
ANNUAL SHAREHOLDER MEETING 24 July 2020
Slide 2: Chairperson’s Address
Chairperson’s Address. Anthony (Tony) Offen Chair, Independent non-executive director
Slide 3: Voting and Asking Questions
Voting and Asking Questions. The voting box Question box
Slide 4: Meeting Agenda
Meeting Agenda. Business of the Meeting Chairperson’s Address • Tony Offen Chief Executive Officer’s Address • Brian Watson Ordinary Resolutions • Election of Tony Balfour as a director. • Director remuneration • Re-appointment of Deloitte as Auditor Other Business
Slide 5: Disclaimer
Disclaimer. In making an investment decision, investors must rely involve significant elements of subjective judgement Information on their own examination of the Company, including the and assumptions as to future events which may or may The information in this presentation is an overview and merit
Slide 6: Board of Directors
Board of Directors. Anthony (Tony) Offen Graeme Boyd Geoffrey Plunket Chair, Independent Deputy Chair, Independent Independent non-executive director non-executive director non-executive director Chair of Audit and Risk Committee Dr Alison Stewart Antony (Tony) Balfour Dr Barry Richardson Independen
Slide 7: Results FY20
Results FY 20. EBITDA 2.1m $ 0.9m $ NZ$ Millions $ 0.6m $ -0.3m $ -0.4m 5 Year Growth Trend 33% FY16 FY17 FY18 FY19 FY20 R + Revenue C AG Year Net Profit 12 5 1.6m $ $ 10.6m 10 NZ$ Millions 8 $ 8.2m 0.4m NZ$ Millions $ $ 6.5m 6 $ 5.6m 0.02m $- 5.3m $ 4 $ -0.8m 2 $- 1.0m 0 FY16 FY17 FY18 FY19 FY20 FY
Slide 8: Strategy
Strategy. Company vision Value proposition Delivering health benefits to global consumers Blis Technologies is a leader in the manufacture of advanced by unlocking the potential of the microbiome. probiotic strains that go beyond the gut. We combine innovation with a strong evidence base and the hig
Slide 9: CEO Address
CEO Address. Brian Watson Chief Executive Officer (CEO)
Slide 10: The BLIS Leadership Team
The BLIS Leadership Team. Brian Watson Richard Wingham Chief Executive Officer (CEO) Chief Financial Officer (CFO) Julie Curphey Dr John Hale Frank Spiewack Chief Marketing Officer (CMO) Chief Technology Officer (CTO) Commercial Director
Slide 11: FY20 Financial Summary
FY20 Financial Summary. 1.6m $ $ 2.1m $ 4.1m $ 10.6m up 130 up 29 Reported profit EBITDA Working capital Revenue for the year % at year end % up 320 % up 1.8m $ FY19 FY20 Change Change ($000) ($000) ($000) % Revenue 8,239 10,642 2,402 +29% Net Surplus before interest expense, tax, depreciation and a
Slide 12: FY20 Operational Summary
FY20 Operational Summary. Continued strong sales Validation of Covid-19 growth on the Amazon US alternative Response online platform second supplier of probiotics • Free product provided ingredient to Pharmacy and GP frontline staff Launch of UltraBLIS™ • Essential Business Be kind. Check-in on the
Slide 13: Strategic priorities
Strategic priorities. SUPPLY POSITIONING CHAIN Ongoing priorities: Positioning • New markets – Canada, CBEC • UltraBLIS next phase launch activity • Continue to expand online presence • BLIS Q24 skincare Supply chain • Alternative offshore ingredient supply PEOPLE • Finished product capacity expansi
Slide 14: Building the BLIS PROBIOTICS brand
Building the BLIS PROBIOTICS brand.
Slide 15: FY20 Regional Sales Performance: North America
• Strong growth of BLIS branded ingredient sales to North America – Customer base with an online North presence performing well America • Continued to expand the customer base through 3.0m new customer launches $ • BLIS finished goods sales on Amazon platform +142% delivered five-fold sales growth i
Slide 16: FY20 Regional Sales Performance: Europe/Middle East
FY20 Regional Sales Performance. Europe/ Middle East $ 4.0m +33% • Steady FY20 growth in new and existing markets Outlook • COVID restrictions have impacted Pharmacy channel and health professional selling • Together with our distributor we are supporting greater online activity
Slide 17: FY20 Regional Sales Performance: Asia Pacific
FY20 Regional Sales Performance. • Excluding Australia, revenue up 31% • Prior year comparison skewed by one-off pipeline fill to support the Australia launch at end of FY19. • Japan continues to deliver strong sales performance Asia • NZ sales + 35% - No1 selling throat lozenge in pharmacy* Pacific
Slide 18: Key COVID-19 Impacts
COVID-19 WORKPLACE HEALTH importance& SAFETY Key COVID-19 • Increased of online sales channel ESSENTIAL PRODUCTS Impacts. • Consumer focus on health and wellbeing including immunity solutions • Supply chain challenges TO HELP YOU RESTART YOUR BUSINESS
Slide 19: Online Sales Channel Importance
Online Sales Channel Habits developed during the crisis Importance. - including online shopping, remote learning, streaming entertainment, working from home - will likely continue to take place • The COVID pandemic Existing market capability at higher rates post COVID. has clearly had a global Eurom
Slide 20: Consumer Focus on Health and Wellbeing
Consumer Focus on Health and Wellbeing. New Product Launch: UltraBLIS™: Probiotic Immune Consumer interest in immunity products. Support for Optimal Performance Our portfolio of products are well positioned to provide immune support through periods of high need including: Winter Travel Intensive spo
Slide 21: Supply Chain Challenges
Supply Chain Challenges. • Increased freight costs • Restricted airfreight availability causing delays and changes to normal supply routes • Volatile demand requiring flexibility and the need for increased capacity
Slide 22: New Market Entry FY21
New Market Entry FY21. Canada • Market validation exercise has provided insight and confidence • Trade presentations and partner engagements made prior to travel restrictions • Future plans will be implemented by inmarket partners China Cross Border e-Commerce • New hire to support market developmen
Slide 23: Key Scientific Services Output
Key Scientific Services Output. Regulatory Research and Development Highlights Region Approval Status • UltraBLIS launched USA • M18 No Objection GRAS Completed • BLIS Q24 Skincare prototypes developed • New dental prototypes developed Canada • K12 Masterfile Completed • M18 Masterfile Completed Jap
Slide 24: Ongoing R&D Priorities
Ongoing R & D Priorities. Health Targets Stage in Commercial Development Early Research Development/ NPD Commercialised BLIS Range: ThroatGuard, Daily Upper Defence, DailyDefence Junior, respiratory, UltraBLIS., TravelProtect, ElitePro. ENT, Immunity Finished product innovation, Expanding the eviden
Slide 25: Breakthrough Technology to Unlock Probiotic Potential in Skincare
Breakthrough Technology to Unlock Probiotic Potential in Skincare. Breakthrough technology Product prototype • Combining a unique strain with an innovative formulation market research completed in • Patented probiotic strain – BLIS Q24® NZ and market • Targeting the cosmetic market: a live topical p
Slide 26: Consumer Validation
Consumer Validation. Key consumer research highlights Before receiving the product my skin • The concept was very well received - it was viewed as was dry and rough, it affected my confidence. unique, credible, relevant and exciting. After using for a month I noticed a healthy natural • “Probiotics
Slide 27: People and Performance
People and Performance. Positive staff response to Meeting the needs of a growing COVID impacts business – ongoing capability build • Maintained momentum across business • e-commerce • Adapted to new working conditions • New Product Development • Finished product capacity increases • China market (C
Slide 28: Outlook
• COVID impact will continue to be monitored Outlook » Represents both risks and opportunities for the company • We have the opportunity to continue to strengthen the BLIS PROBIOTICS brand through acceleration of our new market priorities and leveraging the consumer interest in health and wellbeing
Slide 29: Q1 FY21 Update
Q1 FY21 Update. Unaudited results for the quarter ending 30 June 2020 (Q1 FY21). $ 2.9m Total revenue for the quarter $ 0.4m EBITDA surplus ($2.7m for Q1 FY20) ($0.5m for Q1 FY20) Investment in new markets Full Year guidance and R &D pipeline • Sustained profitable growth, • Market launch Canada del
Slide 30: Questions
Questions. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 31: Attendees Question Process
Attendees Question Process. The voting box Question box
Slide 32: Resolutions
Resolutions. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 33: Attendees Voting Process
Attendees Voting Process. The voting box Question box
Slide 34: Resolution 1
Resolution 1. That Mr Antony Balfour be elected as a director of the Company. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 35: Resolution 2
Resolution 2. That pursuant to NZX Listing Rule 2.11.1, the maximum aggregate amount of remuneration payable by the Company to Directors be increased from $265,000 per annum to $309,000 per annum. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 36: Resolution 3
Resolution 3. That the Directors be authorised to fix the remuneration of the auditors for the ensuing year. Wait for the microphone State your name and whether you are a shareholder or proxy holder.
Slide 37: General Business
General Business. i. B LIS Technologies